PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients
Objective: PB-119, a PEGylated exenatide injection, is a once-weekly glucagon-like peptide-1 receptor agonist. In the present study, we aimed to evaluate the effects of PB-119 on insulin resistance and beta-cell function in Chinese patients with type 2 diabetes mellitus (T2DM) to uncover its antidia...
Main Authors: | Xu Liu, Ling Song, Yuanhui Zhang, Haiyan Li, Cheng Cui, Dongyang Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1088670/full |
Similar Items
-
Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
by: Xu Liu, et al.
Published: (2021-09-01) -
Tmem119 expression is downregulated in a subset of brain metastasis-associated microglia
by: Weili Ma, et al.
Published: (2024-02-01) -
TMEM119 facilitates ovarian cancer cell proliferation, invasion, and migration via the PDGFRB/PI3K/AKT signaling pathway
by: Tianshui Sun, et al.
Published: (2021-03-01) -
Optimisation of novel 4, 8-disubstituted dihydropyrimido[5,4-b][1,4]oxazine derivatives as potent GPR 119 agonists
by: Yuanying Fang, et al.
Published: (2020-01-01) -
GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy
by: Ji Hye Im, et al.
Published: (2018-11-01)